Probiotic Administration Research Articles

Probiotics as an Adjunct Approach to the Prevention and Treatment of Colon Cancer: A Review

Abstract:: One out of every six people in the world is suffering from cancer disease. The major causes of cancer are high consumption of tobacco, high body mass index, and alcoholic beverages with low intake of a healthy diet and limited physical activity. Colon cancer is one of the leading causes of cancer-related morbidity worldwide. In the past few years, probiotics have drawn a lot of interest as potential preventive and therapeutic anticancer agents. This literature review addressed both human and animal research that has explored the association between probiotics and colon cancer. Probiotic administration has remarkable potential for the prevention and treatment of colon cancer through various mechanisms such as inhibiting the growth of cancer cells via apoptosis, improving immune activity, restoring gut microbiota, improving intestinal barrier properties, synthesizing anticarcinogenic compounds, and degrading carcinogenic compounds. Therefore, probiotics emerge as an adjunct therapy, holding the potential to significantly reduce the risk of colorectal cancer.

Gastrointestinal Issues in Depression, Anxiety, and Neurodegenerative Diseases: A Systematic Review on Pathways and Clinical Targets Implications.

Multiple illnesses commonly involve both the Central Nervous System (CNS) and the Gastrointestinal Tract (GI) simultaneously. Consistent evidence suggests that neurological disorders impair GI tract function and worsen the symptomatology and pathophysiology of digestive disorders. On the other hand, it has been proposed that early functional changes in the GI tract contribute to the genesis of several CNS illnesses. Additionally, the role played by the gut in these diseases can be seen as a paradigm for how the gut and the brain interact. We mentioned significant GI symptoms and discussed how the GI tract affects central nervous system illnesses, including depression, anxiety, Alzheimer's disease, and Parkinson's disease in this study. We also explored potential pathophysiological underpinnings and novel targets for the creation of future therapies targeted at gut-brain connections. In this situation, modulating the gut microbiota through the administration of fecal microbiota transplants or probiotics may represent a new therapeutic option for this population, not only to treat GI problems but also behavioral problems, given the role that dysbiosis and leaky gut play in many neurological disorders. Accurate diagnosis and treatment of co-existing illnesses also require coordination between psychiatrists, neurologists, gastroenterologists, and other specialties, as well as a thorough history and thorough physical examination.

The protective effect and immunomodulatory ability of orally administrated Lacticaseibacillus rhamnosus GG against Mycoplasma pneumoniae infection in BALB/c mice.

Mycoplasma pneumoniae represents one of the significant etiologies of community-acquired pneumonia in pediatric patients. However, clinical treatment of M. pneumoniae infection in children has encountered challenges due to the escalating resistance to quinolones. Numerous studies have highlighted the potential of probiotic lactobacillus administration in boosting immune responses to bacterial and viral respiratory infections. In this study, the protective efficacy of pre-oral administration of Lacticaseibacillus rhamnosus GG (LGG), Limosilactobacillus reuteri F275, Lactiplantibacillus plantarum NCIMB 8826, L. plantarum S1 or L. plantarum S2 was evaluated in the BALB/c mice model; it was observed that among these five strains of lactobacillus, the supplementation of LGG exhibited the most significant protective effect against M. pneumoniae infection. Moreover, when administered orally, both live LGG and heat-inactivated LGG have demonstrated efficacy in reducing the burden of M. pneumoniae in the lungs and alleviating pulmonary inflammation. Oral supplementation with LGG resulted in the inhibition of neutrophil recruitment into the lungs and increased recruitment of alveolar macrophages in M. pneumoniae-infected mice. Additionally, LGG supplementation led to increased production of IL-10 and secretory IgA (sIgA), while suppressing the levels of IL-1β, IL-6, IL-17A, and TNF-α in the lungs of mice infected with M. pneumoniae. The data suggests that supplementation with LGG can modulate immune responses, decrease pathogen load, and alleviate inflammatory injury in the lungs of M. pneumoniae-infected mice.

Effect of Probiotics on Sperm Quality in the Adult Mouse.

The administration of probiotics for the treatment of different diseases has gained interest in recent years. However, few studies have evaluated their effects on reproductive traits. The objective of this study was to examine the effect of two mixtures of probiotics, a commercial probiotic (Vivomixx®) and a mix of Lacticaseibacillus rhamnosus GG and Faecalibacterium duncaniae A2-165, on sperm quality in a mouse model. Adult male mice (8months old) were used for two experimental and one control groups (n = 5 each). The probiotics or physiological serum (control) was administered orally, twice a week, during 5weeks. Sperm were collected from the cauda epididymis, and their total number, motility, kinematics, morphology, and acrosome integrity were assessed in recently collected samples and after a 60-min in vitro incubation. Results showed a higher percentage of normal sperm in both experimental groups, with fewer head abnormalities than in the control. Differences were found among groups in the morphometry of sperm heads, being more elongated in mice treated with probiotics. Sperm from probiotic-treated mice showed similar total motility when compared to the controls, although the proportion of progressively moving sperm and their vigor of motility were lower. Sperm swimming descriptors were measured with a CASA system. Velocity parameters were similar among groups whereas linearity was higher in mice treated with the commercial probiotic. These results suggest that the administration of probiotics may increase the proportion of sperm with normal morphology and lead to modifications in sperm head shape that may enhance sperm swimming. Studies using a longer administration period would be useful in further characterizing the effect of these probiotic mixtures on sperm quality and fertilization capacity.

Effect of Probiotics Supplementation on Cortisol Levels: A Systematic Review and Meta-Analysis

Background: Several randomized controlled trials (RCTs) have shown conflicting results on cortisol levels following probiotic administration in healthy and diseased populations. Previous analyses were inconclusive due to limited studies, and evidence is lacking on how these effects vary by health status; region; therapy duration; medications, and use of single or multiple strains. Methods: In this systematic review and meta-analysis (PROSPERO [CRD42024538539]), we searched PubMed, Cochrane Library, Embase, Scopus, Web of Science, CINAHL, ProQuest, and Web of Science Preprints until 13 August 2024, for RCTs on probiotic administration, either alone or combined, across all age groups and without specific medical condition requirements. We applied random-effects meta-analysis, assessed bias using the Cochrane RoB 2 tool, and evaluated evidence certainty with GRADE. Findings: We screened 1739 records and retrieved 46 RCTs (3516 participants). Probiotics supplementation decreased cortisol levels compared to the control arm [46 RCTs; SMD: −0.45; 95% CI: −0.83; −0.07; I2: 92.5%, low certainty]. Among various subgroups; probiotics supplementation decreased the cortisol levels in the subgroups without concomitant medications [37 RCTs; SMD: −0.30; 95% CI [−0.58; −0.03], I2: 88.7%] with a single probiotic strain [30 RCTs; SMD: −0.33; 95% CI: −0.63; −0.028; I2: 88.8%], in a healthy population [35 RCTs; SMD:−0.3; 95% CI: −0.58; −0.03; I2: 88.7] and in the Asia region [21 RCTs; SMD: −0.83; 95% CI: −1.58; −0.07; I2: 95%]. Interpretation: A low level of evidence suggests probiotics might reduce cortisol levels, but more targeted studies are needed to identify variables affecting the response in specific subgroups.

Anti-Bacterial Potential of Multi-strain Probiotics Lactiplantibacillus plantarum (Strain Dad-13 and FNCC-0250) and Lacticaseibacillus paracasei GMRMP-001 against Escherichia coli FNCC-0091 In Vitro and In Vivo

Lactiplantibacillus plantarum Dad-13, Lactiplantibacillus plantarum FNCC-0250 and Lacticaseibacillus paracasei GMRMP-001 are probiotics strain isolated from Indonesian local and traditional fermented foods. This study aims to evaluate the administration of multi-strain probiotics at dose of 109 CFU/mL/day for 14 days against the diarrhea-causing bacteria Escherichia coli FNCC-0091 at a dose of 1011 CFU/mL/day. Thirty rats were randomized and the divided into 5 groups, including control group, skim milk group, single-strain group, multi-strain group and E. coli group. Antibacterial activity was analyzed in vitro, feed intake, body weight were analyzed, microbial analysis was carried out on feces and cecum, short chain fatty acids were analyzed and intestinal morphology was measured. The result showed that the single-strain and multi-strain inhibition zone in in vitro test produces a very strong inhibitory potential (> 9 mm). The number of L. plantarum and L. paracasei increased and the number of E. coli decreased significantly in the feces and cecum of Rat indicating the survival rate of the probiotic bacteria in the digestive tract and their ability to fight pathogenic bacteria. The concentration of acetic acid, propionic acid and butyric acid compounds also increased, indicating that the digestive tract is at a low pH so that it can inhibit the growth of pathogenic bacteria in rats. In addition, consumption of multi-strain probiotics does not have a negative effect on intestinal morphology. The conclusion is that multi-strain probiotics are able to inhibit pathogenic bacteria in vivo and in vitro. HIGHLIGHTS Multi-strain probiotics isolated from traditional Indonesian fermented foods can reduce the potential for diarrhea. Single-strain and multi-strain have the same effectiveness in inhibiting pathogenic bacteria as seen from the growth of the bacteria. Digestive conditions were damaged in rat that were not given probiotic intervention, but when they received probiotic intervention, digestive conditions improved. GRAPHICAL ABSTRACT

The influence of probiotic administration on selected leukocyte subpopulations and the serum amyloid A concentration in the peripheral blood of dairy cows during different lactation periods

The influence of probiotic administration on selected leukocyte subpopulations and the serum amyloid A concentration in the peripheral blood of dairy cows during different lactation periods

Preweaning Megasphaera elsdenii Supplementation in Dairy-Beef Calves: Impact on Performance, Behavior, and Rumen Development

This study evaluates the effects of an oral probiotic capsule containing a live culture of M. elsdenii NCIMB 41125 on performance, feeding behavior, rumen pH VFA, and development of dairy-beef crossbred calves. Thirty-one male dairy-beef crossbred calves (Holstein x Angus; mean ± SD; 45.3 ± 7.1 kg; 8.2 ± 2.0 d old) were enrolled in a blinded, 76-d randomized trial. Calves were randomly assigned to one of 3 treatments: placebo, probiotic capsule administration on d 15, or probiotic capsule on d 15 plus a second capsule on d 39 of the study. Calves were housed individually with ad libitum access to water and calf starter and were fed 7L/d of milk replacer (1050g of powder/d) in 2 meals until d 41, then 3.5L/d in 2 meals until weaning on d 56. Behavioral observations were recorded in 1-min intervals using a wall-mounted camera. Rumen fluid samples were collected on d 14, 35, 49, 58, and 70, and analyzed for pH and VFA. Upon euthanasia on d 77, forestomach weights were recorded, and rumen papillae dimensions were measured. Mixed linear models were used for statistical analysis. Probiotic treatment resulted in greater daily solid feed DMI and ADG, particularly during weaning and postweaning periods. Additionally, probiotic treated calves spent more time drinking water and tended to have lower rumen pH compared with control. Empty rumen weight and papillae area were greater in calves supplemented with the probiotic capsule on d 15 compared with the other treatments. These findings suggest that preweaning M. elsdenii supplementation enhances performance and rumen development in dairy-beef crossbred calves. However, the impacts of timing and number of capsule applications on rumen development and calf performance should be further investigated. Further research should also investigate the probiotic's impact on the rumen microbiome and fermentation dynamics throughout the rearing period using detailed microbiome analysis.

Optimization of a gelatin/carboxymethylcellulose-based probiotic microcapsule and its application in preventing dextran sodium sulfate-induced colitis in mice.

Oral administration of probiotics has demonstrated substantial potential in alleviating colitis. However, most of the ingested microorganisms struggle to survive the harsh conditions of the gastrointestinal tract, leading to decreased efficacy. In the present study, using double emulsification (W1/O/W2) and complex coacervation methods, we developed a gelatin/carboxymethyl cellulose (CMC)-based probiotic microcapsule and analyzed the efficacy of encapsulated probiotics in preventing dextran sodium sulfate (DSS)-induced colitis in mice. Our results reveal that nearly 90% of the encapsulated probiotics remained viable after 30-day storage at 4°C and approximately 38.1% of viable bacteria (4.0 × 108 cfu/g) survived after 4-h simulated gastrointestinal digestion. In a DSS-induced colitis model, pretreatment with probiotics exerted significant protective effects, with the bacterial microcapsule-treated group having superior outcomes to those of the bacterial suspension plus empty carrier group. Probiotic treatments, especially those administered in the encapsulated form, significantly increased fecal short-chain fatty acid contents, and altered the intestinal microbial composition. The family Muribaculaceae, dominant bacteria in the mouse gut, may be the key microorganism involved in the BM regulation process. Our study presents an alternative approach to treating colitis using probiotics. PRACTICAL APPLICATION: The encapsuled probiotic showed remarkable storage stability at 4°C, maintained good vitality after simulated digestion, and gained superior outcomes in preventing colitis. Our results offer an alternative approach for the probiotic preparations aiming to prevent the intestinal inflammation.

Modelling the influence of vitamin D and probiotic supplementation on the microbiome and immune response

Abstract The intestinal microbiota play a critical role in human health and disease, maintaining metabolic and immune/inflammatory health, synthesizing essential vitamins and amino acids and maintaining intestinal barrier integrity. The aim of this paper is to develop a mathematical model to describe the complex interactions between the microbiota, vitamin D/vitamin D receptor (VDR) pathway, epithelial barrier and immune response in order to understand better the effects of supplementation with probiotics and vitamin D. This is motivated by emerging data indicating the beneficial effects of vitamin D and probiotics individually and when combined. We propose a system of ordinary differential equations determining the time evolution of intestinal bacterial populations, concentration of the VDR:1,25(OH)$_{2}$D complex in epithelial and immune cells, the epithelial barrier and the immune response. The model shows that administration of probiotics and/or vitamin D upregulates the VDR complex, which enhances barrier function and protects against intestinal inflammation. The model also suggests co-supplementation to be superior to individual supplements. We explore the effects of inflammation on the populations of commensal and pathogenic bacteria and the vitamin D/VDR pathway and discuss the value of gathering additional experimental data motivated by the modelling insights.

Effect of Lacticaseibacillus rhamnosus IDCC 3201 on irritable bowel syndrome with constipation: a randomized, double-blind, and placebo-controlled trial

Irritable bowel syndrome is a chronic disorder affecting the gastrointestinal tract, negatively impacting patients’ quality of life. Here, we aimed to evaluate the effects of Lacticaseibacillus rhamnosus IDCC 3201 (RH 3201) on irritable bowel syndrome with constipation (IBS-C). In this randomised, double-blind, placebo-controlled trial, a total of 30 subjects with IBS-C were randomly assigned (1:1) to receive 8 weeks of probiotics administration or placebo. Concerning bowel activities, both irritant bowel movements and discomfort caused by constipation showed significant improvement with RH 3201 at 8 weeks. Symptoms including severity of abdominal bloating, frequency of abdominal bloating, and satisfaction of bowel habits based on the irritable bowel syndrome-severity scoring system also ameliorated in the probiotic group. Analysis of the fecal microbiome revealed that the abundance of Bacteroides cellulosilyticus and Akkermansia muciniphila was higher during the period of RH 3201 administration compared to the placebo. Untargeted metabolome analysis further suggested a correlation between specific metabolites, such as N-acetylornithine, xanthine, and 3-phenylpropionic acid, and the improvement of clinical symptoms. These results indicate that RH 3201 was effective in ameliorating IBS-C, potentially by enriching beneficial microbes and associated metabolites in the gut environment.

Complex case of multiple sclerosis with multiple demyelinating locations

Multiple sclerosis (MS) is a chronic inflammatory disorder with an unpredictable progression that affects the central nervous system and has significant emotional, social, and professional implications. The therapeutic approach is multifactorial and requires complex management coordinated by a specialized, multidisciplinary team over the long term. Current non-pharmacological treatment strategies under study, which may improve the course of the disease, focus on the gut microbiome and include the administration of probiotics and fecal transplantation. This study presents a case of secondary progressive multiple sclerosis in a young patient, with rapidly progressive evolution despite ongoing background therapy. The study analyzed literature data regarding both medical rehabilitation programs used in secondary progressive multiple sclerosis and other therapeutic strategies that can improve the quality of life. Medical rehabilitation has no proven impact on disease progression but can enhance the quality of life for patients with multiple sclerosis through spasticity management, improved mental health, increased mobility, and muscle strength. These therapeutic strategies can improve involvement in professional activities and participation in social and family life for patients with multiple sclerosis.

Evaluating the Effect of a Probiotic on Prevention of Diarrhea, Stress Response, and Social Interactions in a Colony of Macaca fascicularis

Background: Social housing changes are associated with diarrhea in macaques, presumably due to stress. Objective: Since probiotics are utilized in humans for diarrhea, we tested the effectiveness of a species- specific probiotic, SDPro™ (composition: ~2 billion CFU each of live Lactobacillus reuteri and Saccharomyces boulardii), to prevent relocation-associated diarrhea. Assessments of the gutmicrobiome and diarrhea severity were made. Behavioral observations and cortisol levels were examined after relocation to test the effects of the probiotic treatment. Methods: The probiotic was administered to 60 juvenile macaques of both sexes (Probiotic +) and outcomes were compared to 60 control (Probiotic -) macaques. The effects on gut microbiome composition were analyzed via 16s microbiome analysis in half the animals from both groups. Social behaviors were monitored twice-weekly in the morning and afternoon for five weeks following 10- days of SDPro™ administration in 56 subjects and hair cortisol was assayed. Results: Probiotic administration altered beta, but not alpha, diversity, and caused changes in taxa abundance at the phylum, genus, and species levels. The Probiotic + group was enriched in Firmicutes, Clostridium, and Lactobacillus and diminished in Bacteriodies (p’s < 0.05) compared to controls. Although SDPro™ did not alter diarrhea incidence following relocation, it reduced diarrhea severity in males only. Males also exhibited higher cortisol levels than females but there was no probiotic effect. Probiotic treatment had minor behavioral effects; the typical reduction in locomotion seen in the afternoon was eliminated. Conclusion: The results suggest that SDPro™ may be a viable tool to prevent relocation-induced diarrhea in juvenile male macaques.

The Effect of Probiotic Administration with Different Time Intervals on Water Quality in Shrimp Cultivation Vaname (Litopenaeus vannamei) Biofloc System

Vaname shrimp is one of the marine fishery commodities that has high economic value. Water in vaname shrimp cultivation must be maintained in quality. Ammonia can be harmful to shrimp, control of ammonia and organic matter content can be done biologically with the application of probiotics. Therefore, this study needs to be conducted to determine the right time interval in providing probiotics to the water quality of vaname shrimp cultivation in the biofloc system. The method used in this study is the experimental method, using RAL with 4 treatment levels and 3 repetitions, with treatment P0 (Once during maintenance), P1 (once every 5 days), P2 (once every 10 days) and P3 (once every 15 days), the probiotic used in this study is the probiotic Probio-7. The results of the study during 56 days of maintenance showed that the average value of water quality salinity 26.7-27 ppt, temperature 27.7-28°C DO 7.13-7.16 mg/L, nitrate 0.63-0.87 mg/L and Total Ammonia 0.76-0.92 mg/L. Based on the research activities that have been carried out, the interval of probiotic administration has a significant effect on water quality. Probiotic administration can increase the Total Ammonia content and reduce the amount of ammonia in this study. Probiotic administration with an interval of 5 days once (P1) gave a total ammonia value of 0.78 mg/L with an ammonia amount of 0.067 mg/L. P1 also gave the highest growth, absolute weight 5.61 g, absolute length 8.82 cm, SGR 5.779%/Day and FCR 1.47.

Gut microbiota metabolites: potential therapeutic targets for Alzheimer's disease?

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive decline in cognitive function, which significantly increases pain and social burden. However, few therapeutic interventions are effective in preventing or mitigating the progression of AD. An increasing number of recent studies support the hypothesis that the gut microbiome and its metabolites may be associated with upstream regulators of AD pathology. In this review, we comprehensively explore the potential mechanisms and currently available interventions targeting the microbiome for the improvement of AD. Our discussion is structured around modern research advancements in AD, the bidirectional communication between the gut and brain, the multi-target regulatory effects of microbial metabolites on AD, and therapeutic strategies aimed at modulating gut microbiota to manage AD. The gut microbiota plays a crucial role in the pathogenesis of AD through continuous bidirectional communication via the microbiota-gut-brain axis. Among these, microbial metabolites such as lipids, amino acids, bile acids and neurotransmitters, especially sphingolipids and phospholipids, may serve as central components of the gut-brain axis, regulating AD-related pathogenic mechanisms including β-amyloid metabolism, Tau protein phosphorylation, and neuroinflammation. Additionally, interventions such as probiotic administration, fecal microbiota transplantation, and antibiotic use have also provided evidence supporting the association between gut microbiota and AD. At the same time, we propose an innovative strategy for treating AD: a healthy lifestyle combined with targeted probiotics and other potential therapeutic interventions, aiming to restore intestinal ecology and microbiota balance. Despite previous efforts, the molecular mechanisms by which gut microbes act on AD have yet to be fully described. However, intestinal microorganisms may become an essential target for connecting the gut-brain axis and improving the symptoms of AD. At the same time, it requires joint exploration by multiple centers and multiple disciplines.

IN VITRO AND IN VIVO INVESTIGATION OF PROBIOTICS ISOLATED FROM HUMAN MILK

People all over the world are embracing probiotics as a result of growing awareness of the health advantages connected to ingesting living bacteria. Proper administration of probiotics has been shown to provide numerous health advantages to the host. The Lactobacillus genus, which naturally resides in the mucosal linings of humans and animals, and it is essential for stabilizing the gastrointestinal tract and protecting intestinal health from infections. There has been a great deal of interest in their potential uses as probiotics, mucosal vaccine vectors, and agents regulating metabolic activities. The present study aimed at isolating and characterizing novel probiotics from human milk and functionally assessing them in vivo for their physiological, enzymatic and antimicrobial activity. Probiotic isolates from human milk were amylolytic, proteolytic and lipolytic and were found to be tolerant to low pH of 3.5, 10% salt and 0.3% bile salt. Primary method of cross streaking and secondary streaking by agar diffusion method revealed antagonistic activity of the isolates against tests pathogens of humans viz., S. aureus Newman, P. fluorescens, S. epidermis and S. aureus. Antibiofilm activity of probiotic isolates in vivo against P. fluorescens and S. aureus Newman indicated that the metabolites present in the Cell Free Supernatant (CFS) of the isolates may have the ability to inhibit the formation of biofilm of pathogenic strains. The most efficient probiotic isolates was identified as Weissella confusa and the NCBI GenBank accession number was obtained. The infected mice administered with probiotic isolate Weissella confusa PS17 showed reduced mortality rate than the mice infected with pathogenic strain S. aureus Newman, thus indicating that probiotic strain boosted the immune response of the mice. The Serum uric acid levels was normalised after the infected mice was treated with W. confusa PS17 and this in turn enhanced the survival rate of mice. The present study indicates that isolate W. confusa PS17 can be a promising candidate in improving the condition of health.

Gut microbiome: A revolution in type II diabetes mellitus.

Type II diabetes mellitus (T2DM) has experienced a dramatic increase globally across countries of various income levels over the past three decades. The persistent prevalence of T2DM is attributed to a complex interplay of genetic and environmental factors. While numerous pharmaceutical therapies have been developed, there remains an urgent need for innovative treatment approaches that offer effectiveness without significant adverse effects. In this context, the exploration of the gut microbiome presents a promising avenue. Research has increasingly shown that the gut microbiome of individuals with T2DM exhibits distinct differences compared to healthy individuals, suggesting its potential role in the disease's pathogenesis and progression. This emerging field offers diverse applications, particularly in modifying the gut environment through the administration of prebiotics, probiotics, and fecal microbiome transfer. These inter-ventions aim to restore a healthy microbiome balance, which could potentially alleviate or even reverse the metabolic dysfunctions associated with T2DM. Although current results from clinical trials have not yet shown dramatic effects on diabetes management, the groundwork has been laid for deeper investigation. Ongoing and future clinical trials are critical to advancing our understanding of the microbiome's impact on diabetes. By further elucidating the mechanisms through which microbiome alterations influence insulin resistance and glucose metabolism, researchers can develop more targeted interventions. The potential to harness the gut microbiome in developing new therapeutic strategies offers a compelling prospect to transform the treatment landscape of T2DM, potentially reducing the disease's burden significantly with approaches that are less reliant on traditional pharmaceuticals and more focused on holistic, systemic health improvements.

Possible application of Akkermansia muciniphila in stress management

Akkermansia muciniphila (A. muciniphila ) is a promising candidate bacterium for stress management due to its beneficial effects on the microbiota-gut-brain axis (MGBA). As a well-known mucin-degrading bacterium in the digestive tract, A. muciniphila has demonstrated significant benefits for host physiology. Recent research highlights its potential in treating several neuropsychiatric disorders. Proposed mechanisms of action include the bacterium’s outer membrane protein Amuc_1100 and potentially its extracellular vesicles (EVs), which interact with host immune receptors and influence serotonin pathways, which are crucial for emotional regulation. Despite its potential, the administration of probiotics containing A. muciniphila faces technological challenges, prompting the development of pasteurized forms recognized as safe by the European Food Safety Authority (EFSA). This review systematically examines the existing literature on the role of A. muciniphila in stress management, emphasizing the need for further research to validate its efficacy. The review follows a structured methodology, including comprehensive database searches and thematic data analysis, to provide a detailed understanding of the relationship between stress, microbiota, and A. muciniphila therapeutic potential.

Changes in the pharyngeal and nasal microbiota in pediatric patients with adenotonsillar hypertrophy.

Adenotonsillar hypertrophy (AH) is considered the main cause of breathing disorders during sleep in children. AH patients, after significant morbidity and often multiple courses of antibiotics, often proceed to tonsillectomy and/or adenoidectomy. Given the potential risks associated with these procedures, there is a growing interest in the use of nonsurgical adjuvant therapies, such as probiotics, that could potentially reduce their need for surgical intervention. In this study, we investigated the pharyngeal and nasal microbiota in patients with AH compared with healthy children. Furthermore, we tested the effects of probiotic spray administration on both disease symptoms and microbiota profiles, to evaluate the possible use of this microbial therapy as an adjuvant for AH patients.

Prevention of Recurrent Spontaneous Preterm Delivery Using Probiotics (Clostridium butyricum, Enterococcus faecium, and Bacillus subtilis; PPP Trial): Protocol for a Prospective, Single-Arm, Nonblinded, Multicenter Trial.

The rate of recurrent spontaneous preterm delivery (sPTD) ranges between 27% and 34% and is 22.3% in Japan. Although it currently remains unclear whether probiotics prevent sPTD, retrospective studies recently reported a reduction in the rate of recurrent sPTD with the administration of probiotics including Clostridium spp., which induce regulatory T cells that play an important role in maintaining pregnancy. The objective of this trial is to evaluate the preventative effects of available oral probiotics, including Clostridium butyricum, on recurrent sPTD. This is a prospective, single-arm, nonblinded, multicenter trial in Japan. The sample size required for this trial is 345 pregnant women with a history of sPTD, considering a clinically significant reduction in the relative risk of 30% (risk ratio=0.7). The primary endpoint is the rate of recurrent sPTD at <37 weeks of gestation. The secondary endpoints are the rate of sPTD at <34 weeks of gestation, the rate of recurrent sPTD at <28 weeks of gestation, the ratio of intestinal Clostridium spp. (detected by next-generation sequencing), and bacterial vaginosis (using the Nugent score). The trial procedures were approved by the Clinical Research Review Board of Toyama University Hospital (SCR2020008) on March 31, 2021. The trial was registered on the Japan Registry of Clinical Trial website on April 28, 2021. Recruitment began on May 1, 2021, and the trial is estimated to finish on March 31, 2025. The findings will clarify the rate of recurrent sPTD following probiotic administration including Clostridium butyricum. Outcomes from this trial will inform clinical practice and guide future randomized controlled trials. Japan Registry of Clinical Trials jRCTs041210014; https://jrct.niph.go.jp/latest-detail/jRCTs041210014. DERR1-10.2196/59928.